spacer
home > ebr > Spring 2004
PUBLICATIONS

European Biopharmaceutical Review

ebr
Spring 2004
At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR.
   
Text
PDF
In her Editor's Letter, Dr Helen Abbott reviews the articles featured in this quarter's EBR  
view
Science and Innovation
Following the tragic events of 9/11, G Steven Burrill, CEO of Burrill & Company, looks at the steps taken to guard against bioterrorism, when he asks Are We Biosecure?  
view
Professor Gordon McVie, Oncology Adviser and Phil Collis, VP of Scientific Affairs at Inveresk, consider three of the greatest challenges facing the pharmaceutical industry in the 21st Century, in CNS, Oncology and HIV Clinical Trials: Current Trends and Future Prospects  
view
Richard Buick, Senior Scientist at Fusion Antibodies Ltd and Christopher Scott, Lecturer in Biomolecular Science at the School of Pharmacy, Queen's University Belfast, consider Protein Antigens for Therapeutic and Diagnostic Antibodies Biodevelopment and Manufacturing  
view
bullet
BioBusiness Development
John Wilkinson and Nicola Maguire, Partners in the Life Sciences Group at Bird and Bird, advise on Preparing for the Due Diligence Process - Plan your Way to Success  
view
In Understanding Due Diligence - Taking a Practical Approach, Patrick Martin, Partner at McGrigors, examines the necessity of due diligence when running a biotech company  
view
Rupert Winckler, Consultant at PharmaVentures, explores the values of licensing deals when he asks, What is a Cancer Drug Worth?  
view
Dimitri F Dimitriou, CEO of DyoDelta Biosciences Ltd, breaks down partnering issues in To Partner or Not to Partner? An Overview of the Partnering Field in the Industry in Four Simple Questions  
view
Can the New Generation of Biomarkers Escape the Commodity Trap? Richard Barker, President at New Medicine Partners investigates the facts  
view
Dr Helen Abbott, Technology Consultant at the London Technology Network and Editor of EBR, presents Science, Innovation and Technology Transfer - A New Model for Knowledge Acquisition by Technology-Based Businesses in London  
view
bullet
Legal, Regulatory and Public Policy
Following the announcement that bovine spongiform encephalopathy (BSE) was found in one cow located in the US, Gail Sofer, Director of Regulatory Services at BioReliance, reviews Recent BSE Concerns and the Relevance of Clearance Studies  
view
Adrian Tombling, Partner, and Rachel Wallis, an Associate at Withers & Rogers, keep us up-to-date with Developments in Patents and Trademarks - Putting IP Protection on the Global Map  
view
Gareth Williams, Patent Attorney and European Trade Mark Attorney at Marks and Clerk, considers the patent as an essential business tool for firms in the biopharmaceutical field, in Patently Better - The Rights and Wrongs of Patent Protection Drug Discovery Technology  
view
bullet
Biodevelopment and Manufacturing
The ICH E5 is designed to expedite the global development and availability of new medicinal products without impacting established safeguards relating to quality or safety between ethnic populations. Dr Jörg Täubel, Managing Director of Richmond Pharmacology, reviews the issues in Bridging Studies - What Questions Should be Asked in Phase I Clinical Research?  
view
Kirk Daly, European Sales Director for CentraLabS Clinical Research, looks at the growing need to test prescription drugs on children, in Paediatric Clinical Trials - The Challenges Facing Central Laboratories  
view
Dr Betsy Hughs-Formella, Managing Director at Bioskin GmbH, challenges us to optimise clinical development programmes and be informed by New Trends in Dermatology Clinical Research  
view
Doris Heger-Mahn, Medical Director and Executive, Astrid Breitschaft, Sub-Investigator and Marjo Ramakers, Research Physician at dinox Clinical Research, review the Challenges in the Development of Hormonal Preparations for Women of a Reproductive Age  
view
Dr Rocky Cranenburgh, Molecular Genetics Team Leader, Alexandra Bloor, Molecular Biologist, Matthew Leckenby, Molecular Biologist and Julian Hanak, Director of Production at Cobra Bio-Manufacturing Plc, consider Engineering Bacteria for DNA Medicine Production  
view
bullet
Drug Discovery
In the second of a two-part series, Nick Haan and Graham Snudden, Co-Founders of BlueGnome Ltd, discuss the techniques used to extract results from microarray images, in Part Two Microarrays in the Real World: Image Analysis  
view
In Allergen Microarrays: A Novel Tool for Improved Target Discovery and Individualised Therapy, Chistian Harwanegg, Senior Scientist, Proteomics and Reinhard Hiller, Head of Proteomics at VBC-GENOMICS Biosciences Research, discuss the application of microarray-based allergen profiling in the field of allergy vaccine development  
view
SD Conzone, Manager of Research and Development and RJ Redkar, R&D Scientist at Schott Nexterion, consider Reproducible, Low Cost Arraying Achieved with a Multiplexed Approach  
view
Tea Gunde, Scientist at ESBATech AG, discusses the application of functional cell-based screenings for the identification of specific RTK inhibitors, in In Vivo Veritas? Cell-Based Assays for Identifying RTK Inhibitors  
view
Dr Mark Whittaker, Scientific Director of the Services Division at Evotec OAI Ltd explains how Drug Hunters become Drug Engineers  
view
Klaus JW May, Director of Sales and Marketing at Genomatix Software GmbH, helps us to understand regulatory networks, in From System Statistics to Systems Biology  
view
bullet
Regional Focus: Germany
Dr Tatiana Kassessinoff, Senior Project Manager at Biopolis Consultants, looks at the region of biosaxony and its growing biotech industry, in biosaxony - In Biotech, Saxony Matters  
view
In SMOs in Germany - Conducting Quality Clinical Trials, Fransois Geelen, General Manager at Geelen and Geelen GmbH, offers an insight into the fast-emerging German SMOs market, which will form a critical catalyst in generating enormous data potential in the future  
bullet
Preview
Freelance Biotech Writer Crispin Littlehales presents A Review of Burrill & Company's 18th Annual Report on the Biotech Industry  
view
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

Sterling Pharma Solutions launches following management buyout


More info >>

White Papers

PROTEIN:PROTEIN INTERACTION ANALYSIS

IBA GmbH

Groth et al., 2007 and Jasencakova et al., 2010 Protein:protein-interactions (PPI) govern almost all important processes in living organisms. Thus, their rapid and accurate determination and investigation is a major challenge in life sciences. The extremely efficient and fast One-STrEP (Twin-Strep) system is suitable for the isolation of functional protein complexes and subsequent mass spectrometry analysis leads to the identification of protein complex components (Junttila et al., 2005) as it is shown in the following studies.
More info >>

Industry Events

Pharma and Device Packaging and Labeling West Coast 2017

28-29 November 2017, Burlingame, California

Following a very successful launch year, we are thrilled to announce that Pharma and Device Packaging and Labeling will be returning to the West Coast for our 2nd annual event.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement